Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study

dc.contributor.author Ratzon, Einav
dc.contributor.author Najajreh, Yousef
dc.contributor.author Salem, Rami
dc.contributor.author Khamaisie, Hazem
dc.contributor.author Ruthardt, Martin
dc.contributor.author Mahajna, Jamal
dc.date.accessioned 2018-09-04T11:31:07Z
dc.date.available 2018-09-04T11:31:07Z
dc.date.issued 2016-02-23
dc.description.abstract Background: Platinum-based drugs are used as cancer chemotherapeutics for the last 40 years. However, drug resistance and nephrotoxicity are the major limitations of the use of platinum-based compounds in cancer therapy. Platinum (IV) complexes are believed to act as platinum prodrugs and are able to overcome some of platinum (II) limitations. Methods: A number of previously sensitized platinum (IV) complexes were evaluated for their anti-cancer activity by monitoring ability to affect proliferation, clonigenicity and apoptosis induction of Cisplatin sensitive and resistant cancer cells. In addition, the uptake of Cisplatin and the platinum (IV) derivatives to Cisplatin sensitive and resistant cancer cells was monitored. Results: The bis-octanoatoplatinum (IV) complex (RJY13), a Cisplatin derivative with octanoate as axial ligand, exhibited strong anti-proliferative effect on the Cisplatin resistant and sensitive ovarian cells, A2780cisR and A2780, respectively. Moreover, RJY13 exhibited good activity in inhibiting clonigenicity of both cells. Anti-proliferative activity of RJY13 was mediated by induction of apoptosis. Interestingly, a bis-lauratopaltinum (IV) complex (RJY6) was highly potent in inhibiting clonigenicity of both Cisplatin sensitive and Cisplatin resistant cells, however, exhibited reduced activity in assays that utilize cells growing in two dimensional (2D) conditions. The uptake of Cisplatin was reduced by 30 % in A2780 in which the copper transporter-1 (Ctr1) was silenced. Moreover, uptake of RJY6 was marginally dependent on Ctr1, while uptake of RJY13 was Ctr1-independent. Conclusions: Our data demonstrated the potential of platinum (IV) prodrugs in overcoming acquired and inherited drug resistance in cancer cell lines. Moreover, our data demonstrated that the uptake of Cisplatin is partially dependent on Ctr1 transporter, while uptake of RJY6 is marginally dependent on Ctr1 and RJY13 is Ctr1-independent. In addition, our data illustrated the therapeutic potential of platinum (IV) prodrugs in cancer therapy. en_US
dc.description.sponsorship This work was supported in part by DFG-RU 728/3-2 to MR, YN and JM. en_US
dc.identifier.uri https://dspace.alquds.edu/handle/20.500.12213/833
dc.language.iso en_US en_US
dc.publisher BioMed Central en_US
dc.subject Platinum (IV) en_US
dc.subject Cisplatin en_US
dc.subject Ovarian cancer en_US
dc.subject Resistance en_US
dc.subject Copper transporter (Ctr1) en_US
dc.title Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study en_US
dc.type Article en_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
RES_14_JOURNAL_paper_1.pdf
Size:
1.52 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: